Drugs / Thymosin α1
Thymosin α1
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06139419 | Jul 2023 → Aug 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03659578 | Aug 2018 → Sep 2021 | non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06966687 | Apr 2025 → Dec 2026 expected | aortic aneurysm | Nanjing Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT03082885 | Apr 2017 → Jun 2019 | liver failure | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT03509688 | Nov 2014 → Dec 2017 | hepatitis | The First Hospital of Jilin University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02127268 Comparator | Apr 2014 → Apr 2020 | myalgic encephalomeyelitis/chronic fatigue syndrome | Zhigang Zhang | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymosin α1 | “This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute pneumonia in non-small cell lung cancer with bulky tumor.” NCT03659578 ↗5“The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC” NCT06139419 ↗ |
| Known as | T-α1 | “Thymosin-α1 (T-α1), a synthetic 28-amino acid peptide” NCT02127268 ↗ |
| Known as | thymosin alpha 1 | “Drug: thymosin alpha 1” NCT03659578 ↗ |
| Modality | Peptide | “a synthetic 28-amino acid peptide” NCT02127268 ↗ |
| Route | Subcutaneous | “s.c injection” NCT03082885 ↗ |